{
  "resourceType": "StructureDefinition",
  "id": "AdverseReactionRiskSummary",
  "extension": [
    {
      "url": "https://aehrc.csiro.au/fhir/StructureDefinition/associated-image",
      "valueReference": {
        "reference": "Binary/IMG19075"
      }
    }
  ],
  "url": "https://aehrc.csiro.au/fhir/logical-models/AdverseReactionRiskSummary",
  "name": "AdverseReactionRiskSummary",
  "title": "Adverse Reaction Risk Summary",
  "status": "draft",
  "publisher": "CSIRO",
  "description": "The Adverse Reaction Risk Summary Logical Model Mindmap is shown below.\n\n<div><img src='data:image/png;base64,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'/></div>\n\nAn adverse reaction risk is a risk of a harmful or undesirable physiological reaction, which is unique to the individual and associated with exposure to a known substance.\n\n**Purpose**\n\nTo record an assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances, and an overview of each related reaction event.\n\n**Supported Models**\n\nAdverse reaction risk, Published archetype [Internet]. openEHR Foundation, openEHR Clinical Knowledge Manager [cited: 2023-12-10]. Available from: https://ckm.openehr.org/ckm/archetypes/1013.1.7022\n\nAdverse reaction event, Published archetype [Internet]. openEHR Foundation, openEHR Clinical Knowledge Manager [cited: 2023-12-10]. Available from: https://ckm.openehr.org/ckm/archetypes/1013.1.5795\n\nAllergyIntolerance, HL7 FHIR Resource [Internet]. Health Level Seven International; [accessed 2023 Dec 10]. Available from: https://hl7.org/fhir/R5/allergyintolerance.html.\n\n**Considerations**\n\n* It is anticipated that this data group will be expanded over time to incorporate additional detail about the propensity and each reaction event.\n* Each adverse reaction risk summary can be included within a curated Adverse reaction or Allergy list (or similar).\n* Substances include, but are not limited to, a therapeutic substance administered correctly at an appropriate dosage for the individual; food; material derived from plants or animals; or venom from insect stings.\n* This archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:\n  * immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or\n  * non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities in individuals with impaired excretion.",
  "fhirVersion": "4.0.1",
  "kind": "logical",
  "abstract": false,
  "type": "https://aehrc.csiro.au/fhir/logical-models/AdverseReactionRiskSummary",
  "baseDefinition": "http://hl7.org/fhir/StructureDefinition/Base",
  "derivation": "specialization",
  "differential": {
    "element": [
      {
        "id": "AdverseReactionRisk",
        "extension": [
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-purpose",
            "valueString": "To record an assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances, and an overview of each related reaction event."
          },
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString": "* It is anticipated that this data group will be expanded over time to incorporate additional detail about the propensity and each reaction event.\n* Each adverse reaction risk summary can be included within a curated Adverse reaction or Allergy list (or similar).\n* Substances include, but are not limited to, a therapeutic substance administered correctly at an appropriate dosage for the individual; food; material derived from plants or animals; or venom from insect stings.\n* This archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:\n  * immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or\n  * non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities in individuals with impaired excretion."
          },
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-mapping",
            "valueString": "Adverse reaction risk, Published archetype [Internet]. openEHR Foundation, openEHR Clinical Knowledge Manager [cited: 2023-12-10]. Available from: https://ckm.openehr.org/ckm/archetypes/1013.1.7022\n\nAdverse reaction event, Published archetype [Internet]. openEHR Foundation, openEHR Clinical Knowledge Manager [cited: 2023-12-10]. Available from: https://ckm.openehr.org/ckm/archetypes/1013.1.5795\n\nAllergyIntolerance, HL7 FHIR Resource [Internet]. Health Level Seven International; [accessed 2023 Dec 10]. Available from: https://hl7.org/fhir/R5/allergyintolerance.html."
          }
        ],
        "path": "AdverseReactionRiskSummary",
        "short": "Adverse Reaction Risk Summary",
        "definition": "An adverse reaction risk is a risk of a harmful or undesirable physiological reaction, which is unique to the individual and associated with exposure to a known substance.",
        "comment": "**Purpose**\n\nTo record an assessment of the propensity for an individual to experience an adverse reaction if exposed, or re-exposed, to a specified substance or class of substances, and an overview of each related reaction event.\n\n**Supported Models**\n\nAdverse reaction risk, Published archetype [Internet]. openEHR Foundation, openEHR Clinical Knowledge Manager [cited: 2023-12-10]. Available from: https://ckm.openehr.org/ckm/archetypes/1013.1.7022\n\nAdverse reaction event, Published archetype [Internet]. openEHR Foundation, openEHR Clinical Knowledge Manager [cited: 2023-12-10]. Available from: https://ckm.openehr.org/ckm/archetypes/1013.1.5795\n\nAllergyIntolerance, HL7 FHIR Resource [Internet]. Health Level Seven International; [accessed 2023 Dec 10]. Available from: https://hl7.org/fhir/R5/allergyintolerance.html.\n\n**Considerations**\n\n* It is anticipated that this data group will be expanded over time to incorporate additional detail about the propensity and each reaction event.\n* Each adverse reaction risk summary can be included within a curated Adverse reaction or Allergy list (or similar).\n* Substances include, but are not limited to, a therapeutic substance administered correctly at an appropriate dosage for the individual; food; material derived from plants or animals; or venom from insect stings.\n* This archetype is intended to provide a single place within the health record to document the propensity for the full range of reactions, from trivial to life-threatening:\n  * immune-mediated: Types I-IV (including allergic reactions and hypersensitivities); or\n  * non-immune-mediated: including pseudo-allergic reactions, side effects, intolerances, and drug toxicities in individuals with impaired excretion.",
        "alias": [
          "Adverse reaction",
          "allergy",
          "intolerance",
          "hypersensitivity"
        ],
        "min": 0,
        "max": "*",
        "type": [
          {
            "code": "BackboneElement"
          }
        ]
      },
      {
        "id": "AdverseReactionRisk.Substance",
        "extension": [
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-example",
            "valueString": "111088007 | Latex |\n256259004 | Pollen |\n102263004 | Eggs (edible) |\n256349002 | Peanut |\n373270004 | Penicillin |\n3738011000036101 | Amoxil |"
          },
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString": "This ADHA value set contains a broad set to support the recording of agents that may be responsible for causing adverse reactions.  This set includes all AMT product Clinicals as well as SNOMED CT-AU substances such as chemical, material and dietary substances"
          }
        ],
        "path": "AdverseReactionRiskSummary.SubstanceName",
        "short": "Substance Name",
        "definition": "Identification of a substance, or substance class, which is considered to put the individual at risk of an adverse reaction event. Both an individual substance and a substance class are valid entries in Substance. A substance may be a compound of simpler substances, for example a medicinal product.",
        "comment": "**Considerations**\n\nThis ADHA value set contains a broad set to support the recording of agents that may be responsible for causing adverse reactions.  This set includes all AMT product Clinicals as well as SNOMED CT-AU substances such as chemical, material and dietary substances\n\n**Example**\n\n111088007 | Latex |\n256259004 | Pollen |\n102263004 | Eggs (edible) |\n256349002 | Peanut |\n373270004 | Penicillin |\n3738011000036101 | Amoxil |",
        "alias": [
          "Agent",
          "Class",
          "Product"
        ],
        "min": 1,
        "max": "1",
        "type": [
          {
            "code": "CodeableConcept"
          }
        ]
      },
      {
        "id": "AdverseReactionRisk.Manifestation",
        "extension": [
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-considerations",
            "valueString": "This AEHRC value set contains the ADHA developed Clinical manifestation reference set, which contains SNOMED CT-AU Clinicals that can be used to describe manifestations"
          },
          {
            "url": "https://aehrc.csiro.au/fhir/StructureDefinition/note-example",
            "valueString": "39579001 | Anaphylaxis |\n126485001 | Urticaria |\n267038008 | Oedema |\n62315008 | Diarrhoea |\n422587007 | Nausea |"
          }
        ],
        "path": "AdverseReactionRiskSummary.Manifestation",
        "short": "Manifestation",
        "definition": "Clinical symptom and/or sign that were observed or associated with the adverse reaction.",
        "comment": "**Considerations**\n\nThis AEHRC value set contains the ADHA developed Clinical manifestation reference set, which contains SNOMED CT-AU Clinicals that can be used to describe manifestations\n\n**Example**\n\n39579001 | Anaphylaxis |\n126485001 | Urticaria |\n267038008 | Oedema |\n62315008 | Diarrhoea |\n422587007 | Nausea |",
        "alias": [
          "Reaction",
          "Nature of reaction",
          "Clinical manifestation"
        ],
        "min": 0,
        "max": "*",
        "type": [
          {
            "code": "CodeableConcept"
          }
        ]
      },
      {
        "id": "AdverseReactionRisk.Comment",
        "path": "AdverseReactionRiskSummary.Comment",
        "short": "Comment",
        "definition": "Additional narrative about the adverse reaction risk not captured in other fields.",
        "alias": [
          "Note"
        ],
        "min": 0,
        "max": "1",
        "type": [
          {
            "code": "string"
          }
        ]
      }
    ]
  }
}